Co-Crystals for Drug Design: A Logical Approach for Modifying Physicochemical Properties of Drugs
Abstract
Drug design plays a critical role in the pharmaceutical industry, addressing the limitations of many compounds with medicinal properties that cannot serve as an effective active pharmaceutical ingredient. Extensive research has been conducted to overcome this challenge, with co-crystals emerging as a promising solution. In drug design, APIs often face challenges such as low solubility, poor mechanical properties, or degradation risks. Since the discovery of co-crystals, their potential applications have expanded significantly. Initially recognised as simple solubility modifiers, recent research emphasises their diverse uses, including flavour masking and the enhancement of mechanical properties. With the commercialisation of co-crystal-based drugs, research has shifted from their potential applications to optimise production methods. This article reviews key production methods, including solvent evaporation and hot-melt extrusion, which enable scalable and ecologically sustainable co-crystal synthesis. Addressing poor physicochemical properties, especially low bioavailability, remains a persistent challenge in pharmaceutical development. Co-crystals present an innovative and efficient solution. An active pharmaceutical ingredient (API) and a co-former are joined by non-covalent interactions to form co-crystals, which are crystalline solids. These structures maintain the natural pharmacological efficacy of pharmaceuticals while improving their physicochemical characteristics, such as stability and solubility. They provide a systematic and rational approach to improve API properties because their design follows well-established crystal engineering principles. This review emphasises the increasing interest in co-crystals and their importance in crystal preparation methods. Co-crystallisation has improved the stability, dissolution rate and solubility of active pharmaceutical ingredients. Although, there are challenges related to scalability, innovative solutions are necessary to ensure consistent and cost-effective production. With ongoing research and advancements in scalable manufacturing, co-crystals are poised to revolutionise pharmaceutical development by overcoming bioavailability challenges and enhancing therapeutic outcomes.
References
Ma P, Toussaint B, Roberti EA, Scornet N, Santos Silva A, Castillo Henríquez L, et al. New lidocaine based pharmaceutical cocrystals: preparation, characterization, and influence of the racemic vs enantiopure coformer on the physico chemical properties. Pharmaceutics. 2023;15:1102. doi: 10.3390/pharmaceutics15041102/S1.
Lemmerer A, Bernstein J, Griesser UJ, Kahlenberg V, Többens DM, Lapidus SH, et al. A tale of two polymorphic pharmaceuticals: pyrithyldione and propyphenazone and their 1937 co crystal patent. Chem Eur J. 2011;17:13445–60. doi: 10.1002/chem.201100667.
Etter MC. Encoding and decoding hydrogen bond patterns of organic compounds. Acc Chem Res. 1990;23:120–6. doi: 10.1021/ar00172a005.
Wang X, Du S, Zhang R, Jia X, Yang T, Zhang X. Drug drug cocrystals: opportunities and challenges. Asian J Pharm Sci. 2021;16:307–17. doi: 10.1016/j.ajps.2020.06.004.
Duggirala NK, Perry ML, Almarsson Ö, Zaworotko MJ. Pharmaceutical cocrystals: along the path to improved medicines. Chem Commun. 2015;52:640–55. doi: 10.1039/c5cc08216a.
Kumar S, Nanda A. Approaches to design of pharmaceutical cocrystals: a review. Mol Cryst Liq Cryst. 2018;667:54–77. doi: 10.1080/15421406.2019.1577462.
Nugrahani I, Kumalasari RA, Auli WN, Horikawa A, Uekusa H. Salt cocrystal of diclofenac sodium L proline: structural, pseudopolymorphism, and pharmaceutics performance study. Pharm. 2020;12:690. doi: 10.3390/pharmaceutics12070690.
Fukte SR, Wagh MP, Rawat S. Coformer selection: an important tool in cocrystal formation. Int J Pharm Pharm Sci. 2014;6(7):9–14.
Childs SL, Stahly GP, Park A. The salt cocrystal continuum: the influence of crystal structure on ionization state. Mol Pharm. 2007;4:323–38. doi: 10.1021/mp0601345.
Liu Y, Zhou Z, Ren X, Li T, Wu H, Li Q, et al. Photoinduced self assembled heterostructures of surface charge controlled metal nucleation on supports for stable and enhanced electrocatalytic hydrogen evolution reaction activity. J Power Sources. 2025;635:236524. doi: 10.1016/j.jpowsour.2025.236524.
Almarsson Ö, Zaworotko MJ. Crystal engineering of the composition of pharmaceutical phases: do pharmaceutical co crystals represent a new path to improved medicines? Chem Commun. 2004:1889–96. doi: 10.1039/b402150a.
Othman MF, Jamburi N, Anuar N, Abd Rahim S, Rohalim NH. Ibuprofen amino acids co crystal screening via co grinding methods. MATEC Web Conf. 2016;69:03002. doi: 10.1051/matecconf/20166903002.
Sathisaran I, Dalvi SV. Engineering cocrystals of poorly water soluble drugs to enhance dissolution in aqueous medium. Pharm. 2018;10:108. doi: 10.3390/pharmaceutics10030108.
Fleischman SG, Kuduva SS, McMahon JA, Moulton B, Bailey Walsh RD, Rodríguez Hornedo N, et al. Crystal engineering of the composition of pharmaceutical phases: multiple component crystalline solids involving carbamazepine. Cryst Growth Des. 2003;3:909–19. doi: 10.1021/cg034035x.
Chen T, Tu L, Wang G, Qi N, Wu W, Zhang W, et al. Multi functional chitosan polymeric micelles as oral paclitaxel delivery systems for enhanced bioavailability and anti tumor efficacy. Int J Pharm. 2020;578:119105. doi: 10.1016/j.ijpharm.2020.119105.
Wu W, Grohganz H, Rades T, Löbmann K. Comparison of co former performance in co amorphous formulations: single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co formers. Eur J Pharm Sci. 2021;156:105582. doi: 10.1016/j.ejps.2020.105582.
Rocha B, de Morais LA, Viana MC, Carneiro G. Promising strategies for improving oral bioavailability of poor water soluble drugs. Expert Opin Drug Discov. 2023;18:615–27. doi: 10.1080/17460441.2023.2211801.
Ciccone L, Tonali N, Nencetti S, Orlandini E. Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1145-62. doi: 10.1080/14756366.
Bolla G, Sarma B, Nangia AK. Crystal engineering of pharmaceutical cocrystals in the discovery and development of improved drugs. Chem Rev. 2022;122:11514–603. doi: 10.1021/acs.chemrev.1c00987.
Gröls JR, Castro Dominguez B. Intelligent mechanochemical design of co amorphous mixtures. Cryst Growth Des. 2022;22:2989–96. doi: 10.1021/acs.cgd.1c01442.
Kumar Bandaru R, Rout SR, Kenguva G, Gorain B, Alhakamy NA, Kesharwani P, et al. Recent advances in pharmaceutical cocrystals: from bench to market. Front Pharmacol. 2021;12:780582. doi: 10.3389/fphar.2021.780582.
Pindelska E, Sokal A, Kolodziejski W. Pharmaceutical cocrystals, salts and polymorphs: advanced characterization techniques. Adv Drug Deliv Rev. 2017;117:111–46. doi: 10.1016/j.addr.2017.09.014.
Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: a review of preparations, physicochemical properties and applications. Acta Pharm Sin B. 2021;11:2537–64. doi: 10.1016/j.apsb.2021.03.030.
Kavanagh ON, Croker DM, Walker GM, Zaworotko MJ. Pharmaceutical cocrystals: from serendipity to design to application. Drug Discov Today. 2019;24:796–804. doi: 10.1016/j.drudis.2018.11.023.
Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol. 2006;7:45–63. doi: 10.2165/00128071-200607010-00005.
Manin AN, Drozd KV, Churakov AV, Perlovich GL. Hydrogen bond donor/acceptor ratios of the coformers: do they really matter for the prediction of molecular packing in cocrystals? The case of benzamide derivatives with dicarboxylic acids. Cryst Growth Des. 2018;18:5254–69. doi: 10.1021/acs.cgd.8b00711.
Ngilirabanga JB, Samsodien H. Pharmaceutical co crystal: an alternative strategy for enhanced physicochemical properties and drug synergy. Nano Sel. 2021;2:512–26. doi: 10.1002/nano.202000201.
Das B, Nayak AK, Mallick S. Thyme oil containing fluconazole loaded transferosomal bigel for transdermal delivery. AAPS PharmSciTech. 2023;24:xx. doi: 10.1208/s12249-023-02698-2.
Surov AO, Ramazanova AG, Voronin AP, Drozd KV, Churakov AV, Perlovich GL. Virtual screening, structural analysis, and formation thermodynamics of carbamazepine cocrystals. Pharmaceutics. 2023;15:803? (article number not provided). doi: 10.3390/pharmaceutics15030836.
Aitipamula S, Chow PS, Tan RBH. Polymorphism in cocrystals: a review and assessment of its significance. CrystEngComm. 2014;16:3451–65. doi: 10.1039/c3ce42008f.
Arunan E, Desiraju GR, Klein RA, Sadlej J, Scheiner S, Alkorta I, et al. Definition of the hydrogen bond (IUPAC Recommendations 2011). Pure Appl Chem. 2011;83:1637–41. doi: 10.1351/pac rec 10 01 02.
C EM. Hydrogen bonds as design elements in organic chemistry. J Phys Chem. 1991;95:4601–10. doi: 10.1021/j100165a007.
Donohue J. The hydrogen bond in organic crystals. J Phys Chem. 1952;56:502–10. doi: 10.1021/j150496a023.
Haskins MM, Zaworotko MJ. Screening and preparation of cocrystals: a comparative study of mechanochemistry vs slurry methods. Cryst Growth Des. 2021;21:4141–50. doi: 10.1021/acs.cgd.1c00418.
O’Malley C, McArdle P, Erxleben A. Formation of salts and molecular ionic cocrystals of fluoroquinolones and α,ω dicarboxylic acids. Cryst Growth Des. 2022;22:3060–71. doi: 10.1021/acs.cgd.1c01509.
Radha Rani E, Venkata Radha G. Engineering cocrystals of paliperidone with enhanced solubility and dissolution characteristics. Arh Farm (Belgr). 2021;71:393–409. doi: 10.5937/arhfarm71-32997.
Stanton SA, Du JJ, Lai F, Stanton G, Hawkins BA, Ong JA, et al. Understanding hygroscopicity of theophylline via a novel cocrystal polymorph: a charge density study. J Phys Chem A. 2021;125:9736–56. doi: 10.1021/acs.jpca.0c09536.
Chan HCS, Kendrick J, Neumann MA, Leusen FJJ. Towards ab initio screening of co crystal formation through lattice energy calculations and crystal structure prediction of nicotinamide, isonicotinamide, picolinamide and paracetamol multi component crystals. CrystEngComm. 2013;15:3799–807. doi: 10.1039/c3ce40107c.
Marchese Robinson RL, Geatches D, Morris C, MacKenzie R, Maloney AGP, Roberts KJ, et al. Evaluation of force field calculations of lattice energies on a large public dataset, assessment of pharmaceutical relevance, and comparison to density functional theory. J Chem Inf Model. 2019;59:4778–92. doi: 10.1021/acs.jcim.9b00601.
Kuminek G, Cao F, Bahia de Oliveira da Rocha A, Gonçalves Cardoso S, Rodríguez Hornedo N. Cocrystals to facilitate delivery of poorly soluble compounds beyond rule of 5. Adv Drug Deliv Rev. 2016;101:143–66. doi: 10.1016/j.addr.2016.04.022.
Cambridge Structural Database System | Computing. [Internet]. n.d. [Cited: 24-Jun-25]. Available from: https://www.ch.cam.ac.uk/computing/software/cambridge-structural-database-system.
Thakuria R, Sarma B, Nangia A. Hydrogen bonding in molecular crystals. Compr Supramol Chem II. 2017;7:25–48. doi: 10.1016/B978-0-12-409547-2.12598-3.
Devogelaer JJ, Meekes H, Tinnemans P, Vlieg E, de Gelder R. Co crystal prediction by artificial neural networks. Angew Chem Int Ed. 2020;59:21711–8. doi: 10.1002/anie.202009467.
Heng T, Yang D, Wang R, Zhang L, Lu Y, Du G. Progress in research on artificial intelligence applied to polymorphism and cocrystal prediction. ACS Omega. 2021;6:15543–50. doi: 10.1021/acsomega.1c01330.
Wang D, Yang Z, Zhu B, Mei X, Luo X. Machine learning guided cocrystal prediction based on large data base. Cryst Growth Des. 2020;20:6610–21. doi: 10.1021/acs.cgd.0c00767.
Wang L, Yan Y, Zhang X, Zhou X. Novel pharmaceutical cocrystal of lenalidomide with nicotinamide: structural design, evaluation, and thermal phase transition study. Int J Pharm. 2022;613:121394. doi: 10.1016/j.ijpharm.2021.121394.
Kumar A, Nanda A. In silico methods of cocrystal screening: a review on tools for rational design of pharmaceutical cocrystals. J Drug Deliv Sci Technol. 2021;63:102527. doi: 10.1016/j.jddst.2021.102527.
Bennett AJ, Matzger AJ. Progress in predicting ionic cocrystal formation: the case of ammonium nitrate. Chem Eur J. 2023;29:xx. doi: 10.1002/chem.202300076.
Mswahili ME, Lee MJ, Martin GL, Kim J, Kim P, Choi GJ, et al. Cocrystal prediction using machine learning models and descriptors. Appl Sci. 2021;11:1323. doi: 10.3390/app11031323.
Vologzhanina AV. Intermolecular interactions in functional crystalline materials: from data to knowledge. Cryst. 2019;9:478. doi: 10.3390/cryst9090478.
Khan HW, Elgharbawy AAM, Bustam A, Moniruzzaman M. Design and selection of ionic liquids via COSMO for pharmaceuticals and medicine. In: Applied Ionic Liquids for Drug Delivery. 2021. p. 137–64. doi: 10.1007/978-981-16-4365-1_8.
Wu D, Zhang B, Yao Q, Hou B, Zhou L, Xie C, et al. Evaluation on cocrystal screening methods and synthesis of multicomponent crystals: a case study. Cryst Growth Des. 2021;21:4531–46. doi: 10.1021/acs.cgd.1c00415.
Bysouth SR, Bis JA, Igo D. Cocrystallization via planetary milling: enhancing throughput of solid state screening methods. Int J Pharm. 2011;411:169–71. doi: 10.1016/j.ijpharm.2011.03.037.
Trivedi HR, Borkar DS, Puranik PK. Experimental design approach for development of cocrystals and immediate release cocrystal tablet of atorvastatin calcium for enhancement of solubility and dissolution. J Res Pharm. 2020;226. doi: 10.35333/jrp.2020.226.
Karagianni A, Malamatari M, Kachrimanis K. Pharmaceutical cocrystals: new solid phase modification approaches for the formulation of APIs. Pharmaceutics. 2018;10:18. doi: 10.3390/pharmaceutics10010018.
Douroumis D, Ross SA, Nokhodchi A. Advanced methodologies for cocrystal synthesis. Adv Drug Deliv Rev. 2017;117:178–95. doi: 10.1016/j.addr.2017.07.008.
Dal Magro C, dos Santos AE, Ribas MM, Aguiar GPS, Volfe CRB, Lopes MLLC, et al. Production of curcumin resveratrol cocrystal using cocrystallization with supercritical solvent. J Supercrit Fluids. 2021;171:105190. doi: 10.1016/j.supflu.2021.105190.
Saraf GJ, Burade KKB, Gonjari ID, Hosmani AH, Pawar AA. A review on advances in pharmaceutical co crystal preparation routes, intellectual property perspective and regulatory aspects. Int J Curr Pharm Res. 2022:4–12. doi: 10.22159/ijcpr.2022v14i5.2038.
Jung S, Choi I, Kim IW. Liquid assisted grinding to prepare a cocrystal of adefovir dipivoxil thermodynamically less stable than its neat phase. Crystals. 2015;5:583–91. doi: 10.3390/cryst5040583.
Karimi Jafari M, Padrela L, Walker GM, Croker DM. Creating cocrystals: a review of pharmaceutical cocrystal preparation routes and applications. Cryst Growth Des. 2018;18:6370–87. doi: 10.1021/acs.cgd.8b00933.
Narala S, Nyavanandi D, Alzahrani A, Bandari S, Zhang F, Repka MA. Creation of hydrochlorothiazide pharmaceutical cocrystals via hot melt extrusion for enhanced solubility and permeability. AAPS PharmSciTech. 2022;23:xx. doi: 10.1208/s12249-021-02202-8.
Pawar N, Saha A, Nandan N, Parambil JV. Solution cocrystallization: a scalable approach for cocrystal production. Cryst. 2021;11:303. doi: 10.3390/cryst11030303.
Wicaksono Y, Setyawan D, Siswandono. Formation of ketoprofen malonic acid cocrystal by solvent evaporation method. Indones J Chem. 2017;17:161–6. doi: 10.22146/ijc.24884.
Urano M, Kitahara M, Kishi K, Goto E, Tagami T, Fukami T, et al. Physical characteristics of cilostazol–hydroxybenzoic acid cocrystals prepared using a spray drying method. Cryst. 2020;10:313. doi: 10.3390/cryst10040313.
Setyawan D, Oktavia IP, Farizka R, Sari R. Physicochemical characterization and in vitro dissolution test of quercetin-succinic acid co-crystals prepared using solvent evaporation. Turk J Pharm Sci. 2017 Dec;14(3):280-284. doi: 10.4274/tjps.16362.
Zu’aimah Barikah K. Traditional and novel methods for cocrystal formation: a mini review. Syst Rev Pharm. n.d.;9:xx. doi: 10.5530/srp.2018.1.15.
Wang IC, Lee MJ, Sim SJ, Kim WS, Chun NH, Choi GJ. Anti solvent co crystallization of carbamazepine and saccharin. Int J Pharm. 2013;450:311–22. doi: 10.1016/j.ijpharm.2013.04.012.
Aghara M, Dudhat K. Solubility and dissolution enhancement of luliconazole by a cocrystal engineering technique with different coformers. J Pharm Innov. 2023;18:1701–12. doi: 10.1007/s12247-023-09751-4.
Wasim M, Mannan A, Asad MHH Bin, Amirzada MI, Shafique M, Hussain I. Fabrication of carbamazepine cocrystals: characterization, in vitro and comparative in vivo evaluation. Biomed Res Int. 2021;2021:6685806. doi: 10.1155/2021/6685806.
Biscaia IFB, Oliveira PR, Gomes SN, Bernardi LS. Obtaining cocrystals by reaction crystallization method: pharmaceutical applications. Pharmaceutics. 2021;13:898. doi: 10.3390/pharmaceutics13060898.
Vaksler YA, Benedis D, Dyshin AA, Oparin RD, Correia NT, Capet F, et al. Spectroscopic characterization of single co-crystal of mefenamic acid and nicotinamide using supercritical CO2. J Mol Liq. 2021;334:116117. doi: 10.1016/j.molliq.2021.116117.
Chakravarty P, Famili A, Nagapudi K, Al‑Sayah MA. Using supercritical fluid technology as a green alternative during the preparation of drug delivery systems. Pharmaceutics. 2019;11:629. doi: 10.3390/pharmaceutics11120629.
Saganowska P, Wesolowski M. DSC as a screening tool for rapid co‑crystal detection in binary mixtures of benzodiazepines with co‑formers. J Therm Anal Calorim. 2018;133:785–95. doi: 10.1007/s10973-017-6858-3.
Dhondale MR, Thakor P, Nambiar AG, Singh M, Agrawal AK, Shastri NR, et al. Co‑crystallization approach to enhance the stability of moisture‑sensitive drugs. Pharmaceutics. 2023;15:189. doi: 10.3390/pharmaceutics15010189.
Chen Y, Li L, Yao J, Ma YY, Chen JM, Lu TB. Improving the solubility and bioavailability of apixaban via apixaban‑oxalic acid cocrystal. Cryst Growth Des. 2016;16:2923–30. doi: 10.1021/acs.cgd.6b00266.
Shaikh R, Singh R, Walker GM, Croker DM. Pharmaceutical cocrystal drug products: an outlook on product development. Trends Pharmacol Sci. 2018;39:1033–48. doi: 10.1016/j.tips.2018.10.006.
Singh M, Barua H, Jyothi VGSS, Dhondale MR, Nambiar AG, Agrawal AK, et al. Cocrystals by design: a rational coformer selection approach for tackling the API problems. Pharmaceutics. 2023;15:1161. doi: 10.3390/pharmaceutics15041161.
Chavan RB, Thipparaboina R, Yadav B, Shastri NR. Continuous manufacturing of co‑crystals: challenges and prospects. Drug Deliv Transl Res. 2018;8:1726–39. doi: 10.1007/s13346-018-0479-7.
Chow PS, Lau G, Ng WK, Vangala VR. Stability of pharmaceutical cocrystal during milling: a case study of 1:1 caffeine‑glutaric acid. Cryst Growth Des. 2017;17:4064–71. doi: 10.1021/acs.cgd.6b01160.
Díaz‑Villamarín X, Piñar‑Morales R, Barrero‑Hernández FJ, Antúnez‑Rodríguez A, Cabeza‑Barrera J, Morón‑Romero R. Pharmacogenetics of siponimod: a systematic review. Biomed Pharmacother. 2022;153:113536. doi: 10.1016/j.biopha.2022.113536.
Ashrafizadeh M, Tavakol S, Ahmadi Z, Roomiani S, Mohammadinejad R, Samarghandian S. Therapeutic effects of kaempferol affecting autophagy and endoplasmic reticulum stress. Phytother Res. 2020;34:911–23. doi: 10.1002/ptr.6577.
Niu J, Wang L, Yuan M, Zhang J, Chen H, Zhang Y. Dual‑targeting nanocarrier based on glucose and folic acid functionalized Pluronic P105 polymeric micelles for enhanced brain distribution. J Drug Deliv Sci Technol. 2020;57:101343. doi: 10.1016/j.jddst.2019.101343.
Wang Y, Liu S, Dong W, Qu X, Huang C, Yan T, et al. Combination of hesperetin and platinum enhances anticancer effect on lung adenocarcinoma. Biomed Pharmacother. 2019;113:108779. doi: 10.1016/j.biopha.2019.108779.
Wu Z, Li C, Chen Y, Liu Q, Li N, He X, et al. Chrysin protects against titanium particle‑induced osteolysis by attenuating osteoclast formation and function by inhibiting NF‑κB and MAPK signaling. Front Pharmacol. 2022;13:793087. doi: 10.3389/fphar.2022.793087.
Geng A, Xu S, Yao Y, Qian Z, Wang X, Sun J, et al. Chrysin impairs genomic stability by suppressing DNA double‑strand break repair in breast cancer cells. Cell Cycle. 2022;21:379–91. doi: 10.1080/15384101.2021.2020434.
Dewi RM, Megawati M, Antika LD. Antidiabetic properties of dietary chrysin: a cellular mechanism review. Mini Rev Med Chem. 2021;22:1450–7. doi: 10.2174/1389557521666211101162449.
Khan A, Ikram M, Hahm JR, Kim MO. Antioxidant and anti‑inflammatory effects of citrus flavonoid hesperetin: special focus on neurological disorders. Antioxidants (Basel). 2020;9:609. doi: 10.3390/antiox9070609.
O’Sullivan A, Long B, Verma V, Ryan KM, Padrela L. Solid‑state and particle size control of pharmaceutical cocrystals using atomization‑based techniques. Int J Pharm. 2022;621:121798. doi: 10.1016/j.ijpharm.2022.121798.
U.S. Food and Drug Administration. Drug trials snapshots: MAYZENT. [Internet]. n.d. Available from: [Cited: 24-Jun-25]. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-mayzent.
Jin YR, Han XH, Zhang YH, Lee JJ, Lim Y, Kim TJ, et al. Hesperetin, a bioflavonoid, inhibits rat aortic vascular smooth muscle cells proliferation by arresting cell cycle. J Cell Biochem. 2008;104:1–14. doi: 10.1002/jcb.21592.
Huang J, Li Y, Huang RK, He CT, Gong L, Hu Q, et al. Electrochemical exfoliation of pillared‑layer metal–organic framework to boost the oxygen evolution reaction. Angew Chem Int Ed. 2018;57:4632–6. doi: 10.1002/anie.201801029.
Wu D, Cao XH, Jia PZ, Zeng YJ, Feng YX, Tang LM, et al. Excellent thermoelectric performance in weak‑coupling molecular junctions with electrode doping and electrochemical gating. Sci China Phys Mech Astron. 2020;63:1–11. doi: 10.1007/s11433-019-1528-y.
Aramini A, Bianchini G, Lillini S, Tomassetti M, Pacchiarotti N, Canestrari D, et al. Ketoprofen, lysine and gabapentin co‑crystal magnifies synergistic efficacy and tolerability of the constituent drugs: pre‑clinical evidences towards an innovative therapeutic approach for neuroinflammatory pain. Biomed Pharmacother. 2023;163:114845. doi: 10.1016/j.biopha.2023.114845.
Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47:3–19. doi: 10.1016/S0169-409X(00)00118-6.
US20220324808A1. Co‑crystal of compound I dihydrochloride and preparation method and use thereof. Google Patents [Internet]. n.d. [Cited: 25-Jun-25]. Available from: https://patents.google.com/patent/US20220324808A1/en.
US20230201147A1. Cocrystal antioxidants of protocatechuic acid with L‑theanine for the treatment of oxidative stress and inflammatory conditions. Google Patents [Internet]. n.d. [Cited: 25-Jun-25]. Available from: https://patents.google.com/patent/US20230201147A1/en.
WO2021022103A1. Cocrystals of posaconazole, methods of making and using same. Google Patents [Internet]. n.d. [Cited: 25-Jun-25]. Available from: https://patents.google.com/patent/WO2021022103A1/en.
US12285396B2. Co‑crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof. Google Patents [Internet]. n.d. [Cited: 25-Jun-25]. Available from: https://patents.google.com/patent/US12285396B2/en.
WO2022263576A1. Co‑crystal of apixaban with a carboxylic acid. Google Patents [Internet]. n.d. [Cited: 25-Jun-25]. Available from: https://patents.google.com/patent/WO2022263576A1/en.
Pathi SL, Chennuru R, Bollineni M. Olaparib co‑crystals and process of preparation thereof. 2021.
WO2021060949A1. Co‑crystalline efinaconazole, and method for producing same. Google Patents [Internet]. n.d. [Cited: 25-Jun-25]. Available Available from: https://patents.google.com/patent/WO2021060949A1/en.
US20210277049A1. Cocrystal of progesterone and preparation method and use thereof. Google Patents [Internet]. n.d. [Cited: 25-Jun-25]. Available Available from: https://patents.google.com/patent/US20210277049A1/en.
WO2021137369A1. Novel cocrystal of empagliflozin. Google Patents [Internet]. n.d. [Cited: 25-Jun-25]. Available Available from: https://patents.google.com/patent/WO2021137369A1/en.
WO2021230198A1. Cocrystal of dihydroquinolinone compound. Google Patents [Internet]. n.d. [Cited: 25-Jun-25]. Available from: https://patents.google.com/patent/WO2021230198A1/en.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).